News Snapshot:
Beijing, Nov 15, : , China will approve its first monoclonal anti-Covid-19 combination therapy by December according to media reports. Monoclonal antibodies are proteins designed to attach to a specific target, in this case the spike protein of SARS-CoV-2, which the virus uses to enter human cells. Monoclonal antibodies, proteins that attach to a target, are proteins that can be used to identify a specific target.In this case, the spike protein from SARS-CoV-2 is what the virus uses to enter human cell. The combination therapy is co-developed by Tsinghua University, the Third People’s Hospital of Shenzhen and Brii Biosciences headquartered...
